Samsung BioLogics under review for pre-IPO fraud

South Korea’s Financial Supersory Service is reviewing Samsung BioLogics for potential financial fraud in the lead up to its W2.25tr ($2.0bn) IPO last year, according to a banker who worked on the listing.